Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT04928300
Recruiting Phase 3

Low Dose Dexmedetomidine Versus Normal Saline in Multiple Fracture Ribs

NCT04928300 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Phase 3
Started
2021-06-12
Last updated
2026-01-02

Condition(s) studied

Rib Fractures

Investigational drug(s) / intervention(s)

Dexmedetomidine →0.9% saline

Dexmedetomidine: low dose dexmedetomidine infusion 0.2 µ/kg/hour IV for 5 days.

0.9% saline: the same dose and duration of normal saline will be given for 5 days.

Study summary

In our study, we assess the diaphragmatic function, pain quality and anti-inflammatory properties between low dose infusion of dexmedetomidine normal saline in patients with multiple fracture ribs on conservative treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adults (age 18-65 years) of American Society of Anaesthesiologists (ASA) physical status I-II * Traumatic multiple fracture ribs 3 ribs or more, who will be subjected to thorough assessments including chest 3D-CT * Undergoing conservative treatment (chest strappings) * Intractable pain with visual analogue scale (VAS) over 6 after traditional therapies * Glasgow Coma Scale (GCS) ≥ 13. Exclusion Criteria: * Multiple traumas to body parts other than chest with an abbreviated injury scale over 3 * Serious head trauma with a Glasgow coma scale lower than 13 * Mechanically ventilated patients * Massive hemothorax * Injury to the trachea or bronchus with requirement for immediate surgery * Dementia * Use of corticosteroids during ICU stay * Sepsis * Continued use of neuromuscular blocking agents and aminoglycosides antibiotic use as they are known risk factors for ICU-acquired weakness and any known hypersensitivity * Contraindication to the study drugs.

Primary outcome measure(s)

  • Ultrasonographic diaphragm function — 5 days
    Diaphragmatic excursion and thickness will be assessed by ultasound for 5 days with diaphragmatic dysfunction (DD) is diagnosed if diaphragmatic excursion is \<10 mm and diaphragmatic thickness is \<2 mm. .

Trial sites (1)

FacilityCityRegionStatus
Assiut university hospital Asyut Assuit Recruiting

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04928300 on ClinicalTrials.gov ↗ ← All trials in Egypt